Apricitabine
(SPD754 / SPD756)

What is apricitabine?

Apricitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI).

Apricitabine is being developed by Avexa, an Australian pharmaceutical company. The drug was first developed by BioChem Pharma (where it was called BCH10618). BioChem Pharma was then sold the Shire Pharmaceuticals (where the drug was called SPD754). Shire then sold the rights to develop the drug to Avexa.

Apricitabine has not yet been evaluated or approved by the U.S. Food and Drug Administration.

Newer Anti-HIV Drugs and How to Use Them: Part I
6-23-2009

Safety Monitoring Board Says Phase 3 Trial of Experimental NRTI Apricitabine Can Go Forward Using Lower Dose
6-16-2009

New NRTI Apricitabine Demonstrates Good Safety in Early Clinical Trial
8/22/08

Apricitabine Effective Against Drug-resistant HIV
8/22/08

HIV and AIDS: Top News Articles   HIV and AIDS: FDA-approved Treatments  HIV and AIDS: Experimental Treatments HIV and AIDS: Library of CME Programs